Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Horowski

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Naunyn-Schmiedeberg'S Archives of Pharmacology|December 1, 1993
The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primatesK W Lange, P A Löschmann, E Sofic, et al.
Gynecologic and Obstetric Investigation|January 1, 1988
Suppression of puerperal lactation by terguride. A double-blind studyP L Venturini, R Horowski, V Fasce, et al.
Advances in Neurology|January 1, 1987
Parenteral administration of lisuride in Parkinson's diseaseM R Luquin, J A Obeso, J M Martínez-Lage, et al.
Clinical Neuropharmacology|April 15, 2006
Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosisC Hofmann, U Penner, R Dorow, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1978
Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humansA Liuzzi, P G Chiodini, G Oppizzi, et al.
Journal of Endocrinological Investigation|October 1, 1980
Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic statesG Verde, P G Chiodini, A Liuzzi, et al.
Clinical Endocrinology|January 1, 1980
Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisurideP G Chiodini, A Liuzzi, G Verde, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 1981
Size reduction of macroprolactinomas by bromocriptine or lisuride treatmentP Chiodini, A Liuzzi, R Cozzi, et al.
Nature|July 10, 1980
The role of D-1 and D-2 receptorsM Schachter, P Bédard, A G Debono, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|November 2, 2004
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind studyM Graf, D Ecker, R Horowski, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Naunyn-Schmiedeberg'S Archives of Pharmacology|December 1, 1993
The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primatesK W Lange, P A Löschmann, E Sofic, et al.
Gynecologic and Obstetric Investigation|January 1, 1988
Suppression of puerperal lactation by terguride. A double-blind studyP L Venturini, R Horowski, V Fasce, et al.
Advances in Neurology|January 1, 1987
Parenteral administration of lisuride in Parkinson's diseaseM R Luquin, J A Obeso, J M Martínez-Lage, et al.
Clinical Neuropharmacology|April 15, 2006
Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosisC Hofmann, U Penner, R Dorow, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1978
Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humansA Liuzzi, P G Chiodini, G Oppizzi, et al.
Journal of Endocrinological Investigation|October 1, 1980
Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic statesG Verde, P G Chiodini, A Liuzzi, et al.
Clinical Endocrinology|January 1, 1980
Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisurideP G Chiodini, A Liuzzi, G Verde, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 1981
Size reduction of macroprolactinomas by bromocriptine or lisuride treatmentP Chiodini, A Liuzzi, R Cozzi, et al.
Nature|July 10, 1980
The role of D-1 and D-2 receptorsM Schachter, P Bédard, A G Debono, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|November 2, 2004
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind studyM Graf, D Ecker, R Horowski, et al.
Pageof 8